Semaglutide cuts major adverse cardiovascular events by 32% across diverse populations, despite GI side effects
Background
Cardiovascular disease (CVD) remains the leading cause of global mortality, with conditions like heart failure and atherosclerotic cardiomyopathy posing major risks. While semaglutide, a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA), has demonstrated cardiovascular benefits, the consistency of its effects across various clinical settings and its overall safety-economic profile have remained uncertain. This meta-analysis aimed to consolidate evidence on semaglutide's impact on MACE and its associated risks.
Study Design
Researchers conducted a systematic review and meta-analysis, searching MEDLINE, Embase, Cochrane CENTRAL, Web of Science, ClinicalTrials.gov, and WHO ICTRP up to January 2025. They identified 11 randomized controlled trials (12 comparisons) involving 25,067 participants, comparing semaglutide (across all doses) with placebo or active controls. A DerSimonian-Laird random-effects model was used to pool data for major adverse cardiovascular events (MACE) and safety outcomes, including gastrointestinal (GI) disorders and gallbladder events.
Results
Semaglutide significantly reduced major adverse cardiovascular events (MACE) by 32% [pooled odds ratio (OR)=0.68; 95% confidence interval 0.52-0.91; 95% prediction interval 0.44-1.04]. This benefit was consistent across all doses and populations, showing low statistical heterogeneity. Point estimates for MACE reduction remained unchanged after censoring all STEP obesity trials (OR=0.70) or both heart-failure trials (OR=0.66), indicating a negligible institution-level effect. Mixed-effects meta-regression analysis revealed greater MACE benefit with lower body weight, LDL- and total cholesterol levels, while lesser benefit was observed with higher age, HbA1c, and blood pressure (all P<0.01). Safety pooling, however, found higher risks of any gastrointestinal (GI) disorder [relative risk (RR)=1.47], gallbladder events (RR=2.37), and discontinuation due to GI intolerance (RR=2.32).
Semaglutide reduced major adverse cardiovascular events by 32% (OR=
0.68; 95% CI 0.52-0.91), demonstrating robust cardiovascular protection.
Key Findings
- Semaglutide reduced major adverse cardiovascular events (MACE) by 32% (OR=
0.68; 95% CI 0.52-0.91). - MACE benefit was consistent across all doses and populations, with low statistical heterogeneity.
- Greater MACE benefit was associated with lower body weight, LDL- and total cholesterol levels (all P<0.01).
- Higher risks were observed for any GI disorder (RR=
1.47), gallbladder events (RR=2.37), and GI-related discontinuation (RR=2.32). - Limited generalizability due to predominant enrollment of White patients and lack of participants from low-income countries.
Why It Matters
Semaglutide offers marked and consistent cardiovascular risk reduction across a broad spectrum of patients and doses, reinforcing its role beyond glycemic control and weight management. This finding suggests that individuals at risk for MACE, even those without diabetes, could benefit significantly from semaglutide. However, users and clinicians must carefully weigh this substantial benefit against the increased incidence of GI side effects and gallbladder events, which can lead to treatment discontinuation. The high cost-effectiveness ratios (US$ 180,000-260,000 per quality-adjusted life-year) also highlight a significant economic barrier, particularly outside of high-income countries. Furthermore, the limited racial and geographic representation in the included trials means that the full generalizability of these benefits and risks to diverse global populations remains to be fully established.
semaglutide
cardiovascular-disease
mace
meta-analysis
glp-1-agonist
obesity